Raleigh, NC (PRWEB) April 23, 2014
Cancer researchers in Korea say they have developed a simpler and less invasive way to diagnose bladder cancer from a urine sample. Details of the new study have just been posted on the Cancer Monthly website. Click here to learn more.
Scientists with the Natural Product Research Institute at Seoul National University have concluded that testing for metabolites, the products of metabolism, in urine is a fast, non-invasive, and highly accurate way to diagnose bladder cancer and even to determine whether cancer has spread beyond the bladder.
The study’s lead author, Dr. Xuan Jin, states, “The cancer group could be clearly distinguished from the control groups on the basis of their metabolomics profiles, even when the hematuric [blood in the urine] group was included.”
The study, published in the journal Oncotarget, tested the new metabolite-based test on 138 patients with confirmed bladder cancer and 121 healthy control subjects, including those who had blood in the urine because of non-cancerous problems. They found that the test could identify bladder cancer with 91.3% accuracy, without the invasiveness of traditional cystoscopy.
“Whether or not this new test replaces current diagnostic methods for bladder cancer, this study is exciting because it suggests that it may be a valuable tool not only for finding the disease early, but also for planning treatment,” says Cancer Monthly’s Managing Editor, Alex Strauss. Bladder cancer is among the top ten most common cancers in the U.S., with an estimated 72,000 new cases occurring annually.
To learn how the new test works and why the Korean scientists believe it could change how bladder cancer is diagnosed, see Accurate New Urine Test Could Simplify Bladder Cancer Diagnosis, available now on the Cancer Monthly website.
Jin, X et al, “Diagnosis of bladder cancer and prediction of survival by urinary metabolomics”, February 17, 2014, Oncotarget, Epub ahead of print, http://www.pubfacts.com/detail/24721970/Diagnosis-of-bladder-cancer-and-prediction-of-survival-by-urinary-metabolomics.
For over ten years, Cancer Monthly has been the only centralized source of cancer treatment results. Patients can see the actual survival rate, quality-of-life indicators, and other key data for approximately 1,500 different cancer treatments. Cancer Monthly provides timely and ground-breaking news on the causes, diagnoses and treatments of the most common cancers including Bladder, Brain, Breast, Colon, Kidney (Renal), Liver, Lung (NSCLC), Ovarian, Prostate and Rectal Cancers, Melanoma, Mesothelioma, and Non-Hodgkin's Lymphoma. Written for patients and their loved ones, Cancer Monthly helps families make more informed treatment decisions.